PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hu, J.* ; Protzer, U. ; Siddiqui, A.*

Revisiting hepatitis B virus: Challenges of curative therapies.

J. Virol. 93:e01032-19 (2019)
Verlagsversion DOI
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
With a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem worldwide, despite an effective prophylactic vaccine and well-tolerated, effective antivirals. HBV causes chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The viral genome persists in infected hepatocytes even after long-term antiviral therapy, and its integration, though no longer able to support viral replication, destabilizes the host genome. HBV is a DNA virus that utilizes a virus-encoded reverse transcriptase to convert an RNA intermediate, termed pregenomic RNA, into the relaxed circular DNA genome, which is subsequently converted into a covalently closed circular DNA (cccDNA) in the host cell nucleus. cccDNA is maintained in the nucleus of the infected hepatocyte as a stable minichromosome and functions as the viral transcriptional template for the production of all viral gene products, and thus, it is the molecular basis of HBV persistence. The nuclear cccDNA pool can be replenished through recycling of newly synthesized, DNA-containing HBV capsids. Licensed antivirals target the HBV reverse transcriptase activity but fail to eliminate cccDNA, which would be required to cure HBV infection. Elimination of HBV cccDNA is so far only achieved by antiviral immune responses. Thus, this review will focus on possible curative strategies aimed at eliminating or crippling the viral cccDNA. Newer insights into the HBV life cycle and host immune response provide novel, potentially curative therapeutic opportunities and targets.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.324
1.047
39
55
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Hepadnaviridae ; Hepatitis B Virus ; Hepatocellular Carcinoma ; Interferons ; Reverse Transcriptase ; Cccdna; Closed Circular Dna; Negative Regulatory Element; Arginine-rich Domain; X-protein; Core Protein; Viral-dna; Reverse Transcription; Epigenetic Regulation; Envelope Proteins; Hbx Protein
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0022-538X
e-ISSN 1098-5514
Zeitschrift Journal of Virology
Quellenangaben Band: 93, Heft: 20, Seiten: , Artikelnummer: e01032-19 Supplement: ,
Verlag American Society for Microbiology (ASM)
Verlagsort 1752 N St Nw, Washington, Dc 20036-2904 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
DOI 10.1128/JVI.01032-19
WOS ID WOS:000488281200027
Scopus ID 85072791832
Erfassungsdatum 2019-10-08
[➜Korrektur melden]